Managing TKI Therapy in CML

preview_player
Показать описание
Michael J. Mauro, MD, discusses the management of ponatinib, including comorbidities to consider and when to dose reduce, and the take-home message for a young patient with relapsed chronic myeloid leukemia.

  1. Targeted Oncology
  2. targeted oncology
  3. oncology
  4. cancer
Рекомендации по теме
Managing TKI Therapy 0:03:54

Managing TKI Therapy in CML

Managing cardiovascular risks 0:01:42

Managing cardiovascular risks associated with lifelong TKI therapy in CML

Understanding the cause 0:02:45

Understanding the cause of TKI resistance to improve management strategies in CML

Efficacy & tolerability 0:06:22

Efficacy & tolerability of available TKI therapies in CML & managing TKI resistance

Managing Toxicities from 0:04:31

Managing Toxicities from BCR-ABL TKIs in CML

Managing Toxicities from 0:09:06

Managing Toxicities from Chronic Myeloid Leukemia Treatment

Managing adverse events 0:00:55

Managing adverse events associated with TKIs in CML

Case 3: TKI 0:07:54

Case 3: TKI Therapy and Treatment Monitoring in CML

Resistance to Targeted-TKI 0:06:51

Resistance to Targeted-TKI Treatment in Patients With CML

CML as an 0:07:32

CML as an Ideal Cancer for Targeted Therapy With TKI

CML molecular monitoring: 0:21:14

CML molecular monitoring: Practical advice

Case 1: TKI 0:05:42

Case 1: TKI Therapy and Sequencing Decisions in CP-CML

Current CML treatments: 0:02:17

Current CML treatments: which TKI to choose?

Rationale for TKI 0:04:12

Rationale for TKI Therapy in Relapsed CML

Outlook for the 0:01:38

Outlook for the management of chronic myeloid leukemia

Management of pediatric 0:02:43

Management of pediatric CP-CML in the TKI era & additional considerations in this patient popula...

Case 1: TKI 0:08:02

Case 1: TKI Therapy in CP-CML

Examples of challenging 0:01:22

Examples of challenging scenarios for TFR in CML & how to manage them

Defining Suboptimal Response 0:03:31

Defining Suboptimal Response to BCR-ABL TKI Therapy in CML

When can TKIs 0:30:14

When can TKIs be stopped in CML?

CML: Frontline BCR-ABL 0:09:14

CML: Frontline BCR-ABL TKI Therapy

Debate: Is It 0:08:49

Debate: Is It Time for Discontinuing TKI Therapy in CML Patients Outside of Clinical Trials?

Outcomes of patients 0:02:32

Outcomes of patients with CML with no molecular response within two years of TKI therapy

Emerging therapeutic approaches 0:01:39

Emerging therapeutic approaches for TKI-resistant CML